daily oral glp-1 receptor agonist orforglipron for adults with obesity Original Article: https://t.co/lNjqjAF5oc Editorial: Next Chapter for Weight Control — Small-Molecule GLP-1 Receptor Agonists? https://t.co/gbnfDsdQOL FDA approves Lilly's Foundayo (orforglipron)

Compared with oral hypoglycemic drugs, patients' compliance with injectable drugs is relatively poor

We recognize the dual benefits of these medications, not only in improving glycemic control but also in aiding weight loss by promoting satiety and slowing gastric emptying

A notable differentiator is its favorable lean mass preservation data

Semaglutide GLP-1 injections for weight loss are used for chronic weight management in both adults and children above the age of 12

Significant weight loss was achieved 12 months after the initiation of pharmacotherapy and the weight loss was higher in the semaglutide group than in the liraglutide group [47]

CNS Drugs